The PennZone

  • Home
  • Entertainment
  • Marketing
  • Books
  • Non-profit
  • Music
  • Education
  • Legal
  • Artificial Intelligence

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • Calling all healthcare process experts: Share your ideas at #HSPI2027 in Orlando
  • OneVizion Appoints Zebra Technologies CIO Matt Ausman to Board of Directors
  • Expansive New Worlds Await Peter Darrach Unveils 'The Cleopard and Other Tales from the Second Skin
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • Dividend Stacker Launches Free Calendar and Alerts for High-Yield ETF Payouts
  • Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
  • ChargeOn Announces Conversational Payment Management Solution
  • King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • SHI Introduces the RP-222B3S, Its Highest-Capacity 4K Pulse Tube Cryocooler
  • Redefining Proactive Care: The Rise of the Hybrid Concierge Medical Model
  • As Canada and America Turn on Each Other, These Two Authors Stay On Speaking Terms
  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • When Hope Feels Gone, Death2life Is Still Here!
  • Sebastian Stroeller Publishes "The MAP Language Canon" — The Complete Practitioner's Guide to Structural Conversation
  • OneVizion Appoints Zebra Technologies CIO Matt Ausman to Board of Directors
  • GLADYS Magazine Celebrates their 18 Year Anniversary!
  • New Townhome Building Released at Heritage at South Brunswick, Offering Private Perimeter Setting and Water Views
  • Comics Veteran on Return of Teenage Mutant Ninja Turtles Characters, 3-D Projects, Collaboration with Original 'Star Wars' Toy Engineer
  • Flexible Plan Investments Announces Retirement of Executive Vice President Renée Toth
  • Sensory Education launches new neuro-affirming psychoeducation book, Sensory Diversity
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
  • Expansive New Worlds Await Peter Darrach Unveils 'The Cleopard and Other Tales from the Second Skin
  • James Dooley Named King of AEO at Ceremony in Leigh, England
  • Calling all healthcare process experts: Share your ideas at #HSPI2027 in Orlando
  • Data Ideology Achieves Elite Partner Status with Snowflake
  • Central Bag Company Partners with WYSIWYG Marketing and Launches a Modern Industrial Website
  • DuoKey launches the World's First Agentic Crypto Agility Platform
  • Counterparts Exhibition - Art is Destiny!
  • Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 1456
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions - 176
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man - 169
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 150
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event - 142
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers - 132
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala - 122
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300 - 109
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd

Similar on PennZone

  • ChargeOn Announces Conversational Payment Management Solution
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
  • Volant Announces Major Partnership with the STEM Racing Canada Program to CHAMPION YOUTH ENGINEERING
  • 54 Million Contract. New Chapter as AI Cybersecurity Platform Expands, Margins Surge & Management Signals Confidence. Cycurion, Inc: (NAS DAQ: CYCU)
  • Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
  • RAS AP Consulting Signals Growth of Managed AP Governance With Digital Expansion, Pipeline Activation, and Trademark Filing Ahead of Esker All Access
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
  • Data Ideology Achieves Elite Partner Status with Snowflake
  • Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI
  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us